167 related articles for article (PubMed ID: 22335967)
1. Naturally acquired immune responses to malaria vaccine candidate antigens MSP3 and GLURP in Guahibo and Piaroa indigenous communities of the Venezuelan Amazon.
Baumann A; Magris MM; Urbaez ML; Vivas-Martinez S; Durán R; Nieves T; Esen M; Mordmüller BG; Theisen M; Avilan L; Metzger WG
Malar J; 2012 Feb; 11():46. PubMed ID: 22335967
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
[TBL] [Abstract][Full Text] [Related]
3. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
4. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
[TBL] [Abstract][Full Text] [Related]
5. Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).
Kangoye DT; Nebie I; Yaro JB; Debe S; Traore S; Ouedraogo O; Sanou G; Soulama I; Diarra A; Tiono A; Marsh K; Sirima SB; Bejon P
PLoS One; 2014; 9(9):e107965. PubMed ID: 25238160
[TBL] [Abstract][Full Text] [Related]
6. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
8. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
Malar J; 2011 May; 10():108. PubMed ID: 21529376
[TBL] [Abstract][Full Text] [Related]
9. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of anti-MSP3 and Pfs230 antibody responses and multiplicity of infection in asymptomatic children from southern Ghana.
Amoah LE; Acquah FK; Ayanful-Torgby R; Oppong A; Abankwa J; Obboh EK; Singh SK; Theisen M
Parasit Vectors; 2018 Jan; 11(1):13. PubMed ID: 29304870
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso.
Cherif MK; Ouédraogo O; Sanou GS; Diarra A; Ouédraogo A; Tiono A; Cavanagh DR; Michael T; Konaté AT; Watson NL; Sanza M; Dube TJT; Sirima SB; Nebié I
BMC Res Notes; 2017 Sep; 10(1):472. PubMed ID: 28886727
[TBL] [Abstract][Full Text] [Related]
13. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
Soe S; Theisen M; Roussilhon C; Aye KS; Druilhe P
Infect Immun; 2004 Jan; 72(1):247-52. PubMed ID: 14688102
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.
Roussilhon C; Oeuvray C; Müller-Graf C; Tall A; Rogier C; Trape JF; Theisen M; Balde A; Pérignon JL; Druilhe P
PLoS Med; 2007 Nov; 4(11):e320. PubMed ID: 18001147
[TBL] [Abstract][Full Text] [Related]
15. Antibody Correlates of Protection from Clinical
Hamre KES; Ondigo BN; Hodges JS; Dutta S; Theisen M; Ayodo G; John CC
Am J Trop Med Hyg; 2020 Dec; 103(6):2174-2182. PubMed ID: 33124533
[TBL] [Abstract][Full Text] [Related]
16. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
Sirima SB; Mordmüller B; Milligan P; Ngoa UA; Kironde F; Atuguba F; Tiono AB; Issifou S; Kaddumukasa M; Bangre O; Flach C; Christiansen M; Bang P; Chilengi R; Jepsen S; Kremsner PG; Theisen M;
Vaccine; 2016 Aug; 34(38):4536-4542. PubMed ID: 27477844
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs.
Bang G; Prieur E; Roussilhon C; Druilhe P
PLoS One; 2011; 6(12):e28165. PubMed ID: 22145028
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.
Esen M; Kremsner PG; Schleucher R; Gässler M; Imoukhuede EB; Imbault N; Leroy O; Jepsen S; Knudsen BW; Schumm M; Knobloch J; Theisen M; Mordmüller B
Vaccine; 2009 Nov; 27(49):6862-8. PubMed ID: 19755144
[TBL] [Abstract][Full Text] [Related]
20. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.
Fowkes FJ; Richards JS; Simpson JA; Beeson JG
PLoS Med; 2010 Jan; 7(1):e1000218. PubMed ID: 20098724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
